Physician profile
Christopher M Tully
NPI 1053585232
$17,493.78
in general payments reported to CMS, 2019-2025
77 companies · $2,001 in 2025
The $2,001 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,549 · 2020: $2,270 · 2021: $2,980 · 2022: $1,696 · 2023: $2,006 · 2024: $1,993 · 2025: $2,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,999.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,773.53 | 2019-2025 | Lynparza, Enhertu, Calquence |
| Seagen INC. | $1,586.54 | 2019-2023 | Padcev, Adcetris, Tukysa |
| E.R. Squibb & Sons, L.L.C. | $1,403.14 | 2019-2025 | Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $1,038.19 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $945.88 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Incyte Corporation | $872.93 | 2019-2025 | Jakafi |
| Janssen Biotech, INC. | $872.25 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Amgen INC. | $799.16 | 2019-2024 | Lumakras, Nplate, Vectibix |
| Daiichi Sankyo INC. | $567.32 | 2020-2025 | Enhertu, Datroway, Injectafer |
| Glaxosmithkline, LLC. | $500.31 | 2020-2025 | Jemperli, Zejula, Blenrep |
| Genentech USA, INC. | $479.26 | 2019-2025 | Phesgo, Itovebi, Perjeta |
| Bayer Healthcare Pharmaceuticals INC. | $413.38 | 2019-2025 | |
| Eisai INC. | $384.32 | 2019-2025 | |
| Astellas Pharma US INC | $343.54 | 2019-2025 | Vyloy, Padcev |
| Genzyme Corporation | $319.32 | 2019-2025 |
Show all 77 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Tully listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.